[HTML][HTML] In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

JD Brody, WZ Ai, DK Czerwinski… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
JD Brody, WZ Ai, DK Czerwinski, JA Torchia, M Levy, RH Advani, YH Kim, RT Hoppe
Journal of clinical oncology, 2010ncbi.nlm.nih.gov
Purpose Combining tumor antigens with an immunostimulant can induce the immune
system to specifically eliminate cancer cells. Generally, this combination is accomplished in
an ex vivo, customized manner. In a preclinical lymphoma model, intratumoral injection of a
Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large,
disseminated tumors.
Abstract
Purpose
Combining tumor antigens with an immunostimulant can induce the immune system to specifically eliminate cancer cells. Generally, this combination is accomplished in an ex vivo, customized manner. In a preclinical lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors.
ncbi.nlm.nih.gov